Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade

Peripheral-immune-checkpoint blockade (P-ICB) with mAbs to PD-1 (nivolumab and pembrolizumab) or PD-L1 (atezolizumab, durvalumab, avelumab) alone or combination with chemotherapy represents a novel active treatment for mNSCLC patients. However, this therapy can be associated to immune-related advers...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Oncol
Asıl Yazarlar: Nardone, Valerio, Giannicola, Rocco, Bianco, Giovanna, Giannarelli, Diana, Tini, Paolo, Pastina, Pierpaolo, Falzea, Antonia Consuelo, Macheda, Sebastiano, Caraglia, Michele, Luce, Amalia, Zappavigna, Silvia, Mutti, Luciano, Pirtoli, Luigi, Giordano, Antonio, Correale, Pierpaolo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2021
Konular:
Oncology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8236817/
https://ncbi.nlm.nih.gov/pubmed/34195086
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.684110
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller